vs

Side-by-side financial comparison of Global Net Lease, Inc. (GNL) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

Ultragenyx Pharmaceutical Inc. is the larger business by last-quarter revenue ($207.3M vs $117.0M, roughly 1.8× Global Net Lease, Inc.). Global Net Lease, Inc. runs the higher net margin — 41.2% vs -62.0%, a 103.2% gap on every dollar of revenue. On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs -15.1%). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs -11.1%).

Global Net Lease, Inc. is a publicly traded real estate investment trust that acquires, owns and manages a diversified portfolio of commercial real estate assets under long-term net lease contracts. Its property portfolio spans North America and Europe, covering industrial, office, retail and other key sectors, serving tenants across multiple industries to deliver consistent long-term returns for shareholders.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

GNL vs RARE — Head-to-Head

Bigger by revenue
RARE
RARE
1.8× larger
RARE
$207.3M
$117.0M
GNL
Growing faster (revenue YoY)
RARE
RARE
+41.0% gap
RARE
25.9%
-15.1%
GNL
Higher net margin
GNL
GNL
103.2% more per $
GNL
41.2%
-62.0%
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
-11.1%
GNL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
GNL
GNL
RARE
RARE
Revenue
$117.0M
$207.3M
Net Profit
$48.2M
$-128.6M
Gross Margin
Operating Margin
94.7%
-54.7%
Net Margin
41.2%
-62.0%
Revenue YoY
-15.1%
25.9%
Net Profit YoY
838.7%
3.5%
EPS (diluted)
$0.14
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GNL
GNL
RARE
RARE
Q4 25
$117.0M
$207.3M
Q3 25
$121.0M
$159.9M
Q2 25
$124.9M
$166.5M
Q1 25
$132.4M
$139.3M
Q4 24
$137.8M
$164.6M
Q3 24
$138.7M
$139.5M
Q2 24
$145.5M
$147.0M
Q1 24
$147.9M
$108.8M
Net Profit
GNL
GNL
RARE
RARE
Q4 25
$48.2M
$-128.6M
Q3 25
$-60.1M
$-180.4M
Q2 25
$-24.1M
$-115.0M
Q1 25
$-189.4M
$-151.1M
Q4 24
$-6.5M
$-133.2M
Q3 24
$-65.6M
$-133.5M
Q2 24
$-35.7M
$-131.6M
Q1 24
$-23.8M
$-170.7M
Operating Margin
GNL
GNL
RARE
RARE
Q4 25
94.7%
-54.7%
Q3 25
-11.7%
-106.9%
Q2 25
33.9%
-64.8%
Q1 25
-21.1%
-102.6%
Q4 24
40.8%
-74.3%
Q3 24
9.3%
-94.6%
Q2 24
42.6%
-79.1%
Q1 24
38.6%
-151.9%
Net Margin
GNL
GNL
RARE
RARE
Q4 25
41.2%
-62.0%
Q3 25
-49.7%
-112.8%
Q2 25
-19.3%
-69.0%
Q1 25
-143.0%
-108.5%
Q4 24
-4.7%
-80.9%
Q3 24
-47.3%
-95.7%
Q2 24
-24.5%
-89.5%
Q1 24
-16.1%
-156.8%
EPS (diluted)
GNL
GNL
RARE
RARE
Q4 25
$0.14
$-1.28
Q3 25
$-0.32
$-1.81
Q2 25
$-0.16
$-1.17
Q1 25
$-0.87
$-1.57
Q4 24
$-0.08
$-1.34
Q3 24
$-0.33
$-1.40
Q2 24
$-0.20
$-1.52
Q1 24
$-0.15
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GNL
GNL
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$180.1M
$421.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.7B
$-80.0M
Total Assets
$4.3B
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GNL
GNL
RARE
RARE
Q4 25
$180.1M
$421.0M
Q3 25
$165.1M
$202.5M
Q2 25
$144.8M
$176.3M
Q1 25
$147.0M
$127.1M
Q4 24
$159.7M
$174.0M
Q3 24
$127.2M
$150.6M
Q2 24
$122.2M
$480.7M
Q1 24
$131.9M
$112.3M
Stockholders' Equity
GNL
GNL
RARE
RARE
Q4 25
$1.7B
$-80.0M
Q3 25
$1.7B
$9.2M
Q2 25
$1.8B
$151.3M
Q1 25
$1.9B
$144.2M
Q4 24
$2.2B
$255.0M
Q3 24
$2.3B
$346.8M
Q2 24
$2.4B
$432.4M
Q1 24
$2.5B
$140.3M
Total Assets
GNL
GNL
RARE
RARE
Q4 25
$4.3B
$1.5B
Q3 25
$4.8B
$1.2B
Q2 25
$5.0B
$1.3B
Q1 25
$5.8B
$1.3B
Q4 24
$7.0B
$1.5B
Q3 24
$7.3B
$1.5B
Q2 24
$7.6B
$1.6B
Q1 24
$8.0B
$1.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GNL
GNL
RARE
RARE
Operating Cash FlowLast quarter
$222.8M
$-99.8M
Free Cash FlowOCF − Capex
$-100.8M
FCF MarginFCF / Revenue
-48.6%
Capex IntensityCapex / Revenue
0.5%
Cash ConversionOCF / Net Profit
4.62×
TTM Free Cash FlowTrailing 4 quarters
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GNL
GNL
RARE
RARE
Q4 25
$222.8M
$-99.8M
Q3 25
$56.0M
$-91.4M
Q2 25
$52.0M
$-108.3M
Q1 25
$59.2M
$-166.5M
Q4 24
$299.5M
$-79.3M
Q3 24
$62.1M
$-67.0M
Q2 24
$70.4M
$-77.0M
Q1 24
$92.2M
$-190.7M
Free Cash Flow
GNL
GNL
RARE
RARE
Q4 25
$-100.8M
Q3 25
$-92.7M
Q2 25
$-110.7M
Q1 25
$-167.8M
Q4 24
$-79.5M
Q3 24
$-68.6M
Q2 24
$-79.0M
Q1 24
$-193.9M
FCF Margin
GNL
GNL
RARE
RARE
Q4 25
-48.6%
Q3 25
-58.0%
Q2 25
-66.5%
Q1 25
-120.5%
Q4 24
-48.3%
Q3 24
-49.2%
Q2 24
-53.7%
Q1 24
-178.2%
Capex Intensity
GNL
GNL
RARE
RARE
Q4 25
0.5%
Q3 25
0.8%
Q2 25
1.5%
Q1 25
1.0%
Q4 24
0.1%
Q3 24
1.2%
Q2 24
1.4%
Q1 24
3.0%
Cash Conversion
GNL
GNL
RARE
RARE
Q4 25
4.62×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

GNL
GNL

Industrial And Distribution Segment$56.0M48%
Office Segment$30.8M26%
Single Tenant Retail Segment$30.2M26%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons